Document is current

Article History

Received: 15 June 2020

Accepted: 7 April 2021

First Online: 10 May 2021

Declarations

:

: Patient tissues used in this work were collected under protocols × 12–0231, × 13–0133, × 16–018, × 17–0312 and × 17–155. The Human Research Ethics Committee approval was obtained through the Sydney Local Health District Ethics Committee, Royal Prince Alfred Hospital zone and the St Vincent’s Hospital Ethics Committee. Written consent was obtained from all patients prior to collection of tissue and clinical data stored in a de-identified manner, following pre-approved protocols. Consent into the study included the agreement to the use of all patient tissue and data for publication. The research described in this study conforms with the principles of the Helsinki Declaration.

: Not applicable.

: No conflicts of interests. R.A.S. has received fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline Australia, Bristol-Myers Squibb, Novartis, Myriad, NeraCare and Amgen. G.V.L. is consultant advisor to Aduro, BMS, Mass-Array, Merck MSD, Novartis, Pierre-Fabre, Roche, Sandoz and Qbiotics. The remaining authors declare that they have no competing interests.